In a filing, Editas Medicine Inc revealed its CEO O’Neill Gilmore Neil unloaded Company’s shares for reported $0.73 million on Mar 05 ’24. In the deal valued at $9.42 per share,77,824 shares were sold. As a result of this transaction, O’Neill Gilmore Neil now holds 327,470 shares worth roughly $2.2 million.
Then, Mei Baisong sold 20,327 shares, generating $191,425 in total proceeds. Upon selling the shares at $9.42, the SVP, CHIEF MEDICAL OFFICER now owns 141,543 shares.
Before that, Eaton Bruce sold 103 shares. Editas Medicine Inc shares valued at $1,122 were divested by the EVP, CBO AND CTO at a price of $10.90 per share. As a result of the transaction, Eaton Bruce now holds 74,791 shares, worth roughly $0.5 million.
Citigroup upgraded its Editas Medicine Inc [EDIT] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in mid October from “an Underweight” to “a Neutral”. Cantor Fitzgerald also remained covering EDIT and has decreased its forecast on October 17, 2023 with a “Neutral” recommendation from previously “an Overweight” rating. Stifel revised its rating on September 29, 2023. It rated EDIT as “a Buy” which previously was an “a Hold”.
Price Performance Review of EDIT
On Friday, Editas Medicine Inc [NASDAQ:EDIT] saw its stock fall -1.32% to $6.72. Over the last five days, the stock has lost -9.43%. Editas Medicine Inc shares have fallen nearly -33.66% since the year began. Nevertheless, the stocks have fallen -3.59% over the past one year. While a 52-week high of $11.91 was reached on 02/28/24, a 52-week low of $6.08 was recorded on 04/05/24. SMA at 50 days reached $7.98, while 200 days put it at $8.50. A total of 1.25 million shares were traded, compared to the trading of 1.81 million shares in the previous session.
Levels Of Support And Resistance For EDIT Stock
The 24-hour chart illustrates a support level at 6.61, which if violated will result in even more drops to 6.50. On the upside, there is a resistance level at 6.84. A further resistance level may holdings at 6.95. The Relative Strength Index (RSI) on the 14-day chart is 32.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.54, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.51%. Stochastics %K at 8.30% indicates the stock is a buying.
How much short interest is there in Editas Medicine Inc?
A steep rise in short interest was recorded in Editas Medicine Inc stocks on Mar 15, 2024, growing by 1.34 million shares to a total of 13.93 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 12.59 million shares. There was a rise of 9.62%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 23.92% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.91.
